Cogent Biosciences COGT
NASDAQ COGT
$34.76 -0.19 (-0.54%)
As of: Sep 4, 2026 · 3:59 PM EDT

Cogent Biosciences (COGT) Total Debt (2025)

Cogent Biosciences (COGT) posted quarterly Total Debt of $44.2 million for Q3 2025, up 0.68% quarter-over-quarter from $43.9 million in Q2 2025.

Analysis

Cogent Biosciences (COGT) Total Debt (2025) Analysis & Trends

Cogent Biosciences (COGT) has reported Total Debt for 1 consecutive years, with $44.2 million the latest figure, recorded in Q3 2025.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.07 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.34 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Cogent Biosciences 5.94 Bn 5.94 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 44.25 Mn
Jun 30, 2025 43.95 Mn